MarthaRalucaNeaguMDPhD

PubMed

• 27 citations
  Losartan controls immune checkpoint blocker-induced edema and improves survival in glioblastoma mouse models.
  Meenal Datta, Sampurna Chatterjee, Elizabeth M Perez, Simon Gritsch, Sylvie Roberge
  Proceedings of the National Academy of Sciences of the United States of America. 2023-02-07
• 20 citations
  Lv4 Is a Capsid-Specific Antiviral Activity in Human Blood Cells That Restricts Viruses of the SIVMAC/SIVSM/HIV-2 Lineage Prior to Integration.
  Massimo Pizzato, Sean M. McCauley, Martha R. Neagu, Thomas Pertel, Claudia Firrito
  Plos Pathogens. 2015-07-16
• 80 citations
  Protection against Simian Immunodeficiency Virus Vaginal Challenge by Using Sabin Poliovirus Vectors
  Shane Crotty, Christopher J. Miller, Barbara L. Lohman, Martha R. Neagu, Lara Compton
  Journal of Virology. 2001-08-15

Journal Articles

• Pitfalls in the neuroimaging of glioblastoma in the era of antiangiogenic and immuno/targeted therapy – detecting illusive disease, defining response  
  Huang RY, Neagu MR, Reardon DA and Wen PY, Front. Neurol., 1/1/2015
• How Treatment Monitoring Is Influencing Treatment Decisions in Glioblastomas  
  Neagu MR, Huang RY, Reardon DA and Wen PY, Current Treatment Options in Neurology, 1/1/2015
• Lv4 Is a Capsid-Specific Antiviral Activity in Human Blood Cells That Restricts Viruses of the SIVMAC/SIVSM/HIV-2 Lineage Prior to Integration  
  Pizzato M, McCauley SM, Neagu MR, Pertel T, Firrito C, Ziglio, S, Dauphin A, Zufferey M, Berthoux L, Luban J, PLOS Pathogens, 1/1/2015
• An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors  
  Neagu MR, Reardon DA, Current Treatment Options in Neurology, 1/1/2015
• Join now to see all

Books/Book Chapters

• Clinical Practice: Neurological Complications of Cancer and Its Treatment 
  Chapter: Neurological Complications of Immune-Based Cancer Neurology 
  Neagu MR, Jenkins RW, Reardon DAEditors: David Schiff, MD, Isabel Arrillaga, MD, PhD, Patrick Y. Wen, MD.Edition 3rd,

Abstracts/Posters

• Defining molecular mechanisms of resistance to Glioblastoma (GBM) immunity using a novel CRISPR/Cas9 in vivo loss-of-function screening platform
  Neagu MR, American Association for Cancer Research; American Academy of Neurology, Washington, DC, 2017; Boston, MA, 2017, 1/1/2017
• Extracranial Glioma - A Rare Complication of High-Grade Glial Tumors (HGG)
  Neagu MR, American Academy of Neurology, Vancouver, BC, Canada, 1/1/2016
• In vivo Multiplexed Interrogation of Amplified Genes for Identification of Driver Oncogenes in Ovarian Cancer and Glioblastoma
  Neagu MR, Pediatric Low Grade Astrocytoma Foundation, Boston, MA, 1/1/2014
• Diffusion tensor imaging in brainstem tuberculoma
  Neagu MR, American Academy of Neurology, San Diego, CA, 1/1/2013
• HIV-1 inhibition by humanized TRIMCyp
  Neagu MR, Molecular and Cellular Determinants of HIV Pathogenesis; Cold Spring Harbor: Retroviruses, Whistler, Canada, 2007; Cold Spring Harbor, NY, 2008, 1/1/2008
• TRIM5-mediated restriction in the context of cell-to-cell transfer of HIV-1
  Neagu MR, Cold Spring Harbor: Retroviruses, Cold Spring Harbor, NY, 1/1/2008
• Join now to see all

Lectures

• Primary Brain Tumors – A clinical Review 
  1/1/2015
• Functional Genomics Approaches to Solving the GBM Puzzle 
  1/1/2014
• HIV-1 inhibition by TRIM5-cyclophilin A fusion proteins engineered of human components 
  1/1/2009
• Live poliovirus vector based candidate SIV vaccine 
  1/1/2000
• Join now to see all

Other

• HIV-1 Inhibition By Human TRIM5-CYP Fusion Proteins (Ph.D. Thesis) 
  Neagu MR, Columbia University
  1/1/2009